IFF Expands Partnership With Kemira To Commercialize New Designed Enzymatic Biomaterials
Portfolio Pulse from Benzinga Newsdesk
IFF (NYSE:IFF) is expanding its partnership with Kemira to commercialize a new portfolio of renewable polymers derived from IFF's Designed Enzymatic Biomaterials (DEB) technology. These biopolymers, made from plant sugars, will be produced at industrial scale and integrated into Chemigate Ltd's biorefinery in Finland, operational by mid-2024. The collaboration aims to supply alternatives to fossil-based synthetic polymers for various markets, including pulp, paper, packaging, and water treatment. IFF's DEB technology, initially launched for home and personal care markets, will now offer high-performance material solutions to promote a circular bioeconomy. The materials will expand IFF's AURIST™ biopolymers and Nuvolve® engineered polysaccharides product lines.
December 19, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IFF's expansion into commercializing renewable polymers with Kemira showcases its commitment to sustainability and innovation. The move to supply high-performance biopolymers at an industrial scale is expected to strengthen IFF's product offerings and market position in the bioeconomy sector.
The announcement of IFF's partnership with Kemira to commercialize renewable polymers is likely to be viewed positively by investors who are increasingly focused on sustainability. The ability to produce these materials at an industrial scale could open up new revenue streams for IFF and potentially increase its competitiveness in the market. The positive environmental impact of these products also aligns with growing consumer and regulatory demands for sustainable solutions.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90